The epidemiology, diagnosis and management of scrub typhus disease in China

Hum Vaccin Immunother. 2021 Oct 3;17(10):3795-3805. doi: 10.1080/21645515.2021.1934355. Epub 2021 Jun 14.

Abstract

Thirty-nine years ago, scrub typhus (ST), a disease, was not among the China's notifiable diseases. However, ST has reemerged to become a growing public health issue in the southwest part of China. The major factors contributing to an increased incidence and prevalence of this disease include rapid globalization, urbanization, expansion of humans into previously uninhabited areas, and climate change. The clinical manifestation of ST also consists of high fever, headache, weakness, myalgia, rash, and an eschar. In severe cases, complications (e.g. multi-organ failure, jaundice, acute renal failure, pneumonitis, myocarditis, and even death) can occur. The diagnosis of ST is mainly based on serological identification by indirect immunofluorescence assay and other molecular methods. Furthermore, several groups of antibiotics (e.g. tetracycline, chloramphenicol, macrolides, and rifampicin) are currently effective in treating this disease. This fact suggests the need for robust early diagnostic techniques, increased surveillance, and prompt treatment, and develop future vaccine.

Keywords: Orientia tsutsugamushi; Scrub typhus; china; diagnosis; prevalence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • China / epidemiology
  • Fluorescent Antibody Technique, Indirect
  • Humans
  • Orientia tsutsugamushi*
  • Scrub Typhus* / diagnosis
  • Scrub Typhus* / drug therapy
  • Scrub Typhus* / epidemiology

Substances

  • Anti-Bacterial Agents

Grants and funding

This study was funded by a grant from the Jiangsu Provisional Social Sciences Foundation Grant number [13TYA001].